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Summary l 
OX40 is a member of the TNFINGF-receptor family ex- 
pressed on activated T cells, whose ligand is found 
on activated T and B cells. In the present study, we 
show that cross-linking of OX4OL on CD40L-stimulated 
Bcells, algD dextran-stimulated Bcells, or both results 
in a significantly enhanced proliferative response with 
no change in the cell survival rate. Furthermore, OX40 
stimulation increases immunoglobulln heavy chain 
mRNA levels and immunoglobulin secretion, which 
could not be blocked by anti-cytokine antibodies. In 
additlonal molecular studies, we show that OX4OL 
cross-linking results In the down-regulation of the 
tmnscrlption factor BSAP. This, in turn, leads to a 
change in the in vivo binding pattern of the Immuno- 
globulin heavy chain gene 3’ a enhancer, suggesting 
its activation. This effect may thus be one mechanism 
for 0X40-induced Increase in immunoglobulin secre- 
tion. In conclusion, our data suggest that the 0X40- 
OX4OL interaction is a novel pathway in T cell-depen- 
dent B cell proliferation and differentiation. 
Introduction 
The tumor necrosis factor receptor (TNFR)/netve growth 
factor receptor (NGFR) superfamily of receptors and their 
ligands consist of a growing number of receptor-ligand 
pairs with important functions in lymphocyte activation, 
differentiation, and survival. In mammals, this family in- 
cludes NGFR, TNFR, CD40, FAS (Apo-1), CD30, CD27, 
4-l BB, and 0X40, the focus of the present study (for re- 
view see Armitage, 1994). The receptor members of this 
superfamily are type I membrane molecules and are struc- 
turally homologous: each contains in its extracellular do- 
main 3-4 imperfect repeats of approximately 40 residues, 
anchored by a superimposable pattern of six cysteines. The 
ligand members, on the other hand, are type II membrane 
molecules, the extracellular domains of which form 8 jelly- 
roll folds with demonstrated (Eck et al., 1992; Jones et al., 
1989) or suspected (Peitsch and Jongeneel, 1993) binding 
sites for trimerization. These ligands also have highly con- 
served intracytoplasmatic regions across species, s 
gesting that the so-called ligands are coupled to in 
cellular signaling molecules, thus blurring the distinci 
between receptor and ligand (Smith et al., 1994). Evider 
for this hypothesis has been provided by a recent stu 
demonstrating that CD40 is able to costimulate anti-C 
activated CD4+ T cells through CD40 ligand (CD4OL) (C 
abyab et al., 1994). 
The CD40-CD4OL (gp39) receptor-ligand pair is ac 
ally among the best investigated of those in the TNI 
NGFRsuperfamily, especially in regard to T-Bcell inter 
tions. CD40L (gp39) is highly expressed on activate 
cells (Armitage et al., 1992; Noelle et al., 1992; Lam 
al., 1992) and has been shown to be largely respons 
for T ceil-dependent B cell activation, proliferation, I 
differentiation (especially for isotype switch differentiat 
germinal center formation, and B cell memory) in vitro 
well as in vivo through its ability to interact with Cl 
expressed on resting and activated B cells (Foy et 
1994; for review see Banchereau et al., 1994). 
Recently, 0X40-0X40 ligand (OX4OL), a relatively I 
receptor-ligand pair belonging to the TNFR/NGFR su( 
family has been described, which has a cellular distr 
tion suggesting a role in T-B cell interactions. OX40 1 
first identified on activated rat CD4+ T cells (Paterso 
al., 1987). In subsequent studies, the homology with 
TNFRlNGFR family was demonstrated by sequencing 
OX40 cDNA of various species (rat, mouse, and hun 
(Mallett et al., 1990; Calderhead et al., 1993; Latza 81 
1994). In functional studies, OX40 was shown to exl 
restricted expression on activated T cells, and the liga 
of OX40 with a monoclonal antibody resulted in incree 
T cell proliferation in response to concanavalin A an 
the mixed lymphocyte reaction (Paterson et al., 1987). 
OX40 ligand (OX4OL) has also been identified, altha 
there is some controversy regarding its cellular distribr, 
and molecular mass. Thus, the cloning of the human O> 
from an Epstein-Barr virus (EBV)-transformed, phorbol 
ristate acetate (PMA)- and ionomycin-acttvated B cell 
demonstrated a 34 kDa protein (Godfrey et al., 1E 
which is homologous to a previously described sur 
molecule expressed by a HTLV-1 infected T cell line (N 
et al., 1991). In addition, Baum and coworkers (1994 
cently sequenced the murine OX4OL cDNA, revealin 
apparent molecular mass of 28-28 kDa, which was fc 
on activated T cells but not on LPS-activated 6 cell 
contrast, another study reported that the murine 0) 
is expressed on activated B cells in vitro and in vivo I 
dominantly in the periarteriolar lymphoid sheath [Pi 
of the spleen) with an apparent molecular mass of 70 
(Calderhead et al., 1993). However, in view of the ah 
mentioned cloning data, this described 70 kDa mole 
may more likely represent a polymerized form of OX 
In the present study, we show that the murine 0: 
is strongly expressed on CD40L- and anti-immunoglo 
D (algD) dextran-activated high density splenic B cell! 
has an apparent molecular mass of approximately 2 
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Figure 1. OX4OL Expression by Activated Splenic B Cells: Flow Cy- 
tometry, FIT-PCR, and lmmunoprecipitation 
(A) High density splenic B cells were incubated with algD dextran (1 
@ml), CD4OL L cells (B celVCD40L L cell ratio, lO:l), CD40L L cells 
plus algD dextran for 36 hr. Cells were subsequently stained with 
0X40-immunoglobulin (15 @ml) and goat anti-human Fey-PE in the 
presence of antiGDWCD32 (2.4G2). Human IgG was used to control 
for unspecific staining. B cells alone or in the presence of L cells did 
not express OX4OL after 36 hr (data not shown). Lcells were eliminated 
from data analysis by forward scatter gating. 
(6) Splenic B cells were either taken directly after cell preparation or 
stimulated with CD4OL-CD6 fusion proteirj plus algD dextran for 24 
or 36 hr and total cellular RNA was prepared. RT-PCR for OX4OL 
in Experimental Procedures. The amplified PCR products have the 
expected size (606 bp) and the specificity was confirmed by digestion 
with specific restriction endonucleases. 
(C) Splenic B cells were either stimulated for 36 hr with the CD4OL- 
CD6 fusion protein plus algD dextran (1 @ml) or were taken directly, 
unstimulated after cell preparation, and immunoprecipitation was per- 
formed using 0X40-immunoglobulin or (as control) CD&immuno- 
globulincoated immunobeads. Excess (10x) of unbound 0X40- 
immunoglobulin was added to examine specificity. 
kDa. Its cross-linking results in increased 6 cell prolifera- 
tion and immunoglobulin secretion, which may be due to 
an increased activity of the immunoglobulin heavy chain 
3’ a enhancer. 
Results 
Expression of OX4OL on Activated B Ceils 
In previous studies, it was shown that activated B cells, 
such as peritoneal B cells expressing high levels of major 
histocompatibility complex (MHC) class II antigen or B 
cells in the PALS following immunization with specific anti- 
gen, express OX4OL (Calderhead et al., 1993). In initial 
studies we therefore determined the types of in vitro cell 
activation necessary for such expression. We found that 
lipopolysaccharide (LPS) stimulation of B cells (10 or 20 
@ml) results in OX4OL expression in 20%-300/b of the 
B cells, as determined by binding of the fusion protein 
0X40-immunoglobulin (0X40-lg; data not shown); in con- 
trast, as shown in Figure 1 A, stimulation with anti-IgD dex- 
Van or CD4OL-expressingfibroblasts (CD4OL Lcells) led to 
expression of OX4OL in virtually all B cells and the highest 
expression levels were obtained when both stimuli were 
combined. We also determined the kinetics of OX4OL ex- 
;gO Induces B Cell Proliferation and Differentiation 
Figure 2. B Cell Proliferation in Response to OX4OL Cross-Linking 
At the end of a 3 day incubation period, [W]TdR was added to splenic 
B cells (1Ob cells) coincubated with CD4OL L cells or L cells (B cell/L 
cell ratio, 1011) with or without algD dextran (1 rig/ml) in the absence 
or presence of 0X40-immunoglobulin (0.03-3 @ml). Human IgG, 
CTLACIg, or CD40-immunoglobulin (as controls) did not enhance B 
cell proliferation under all investigated conditions (data not shown). 
Data represent one of three to four separate experiments. 
pression and found that OX4OL expression on activated 
B cells is first detected after 18 hr, peaks after 38-48 hr, 
and then gradually declines; this expression pattern was 
not influenced by interleukin-2 (IL-2), IL-4, IL-5, or IL-10 
(data not shown). In further studies, we performed reverse 
transcriptase-polymerase chain reaction (FIT-PCR) to in- 
vestigate OX4OL mRNA expression. To eliminate L cell 
mRNA, we performed these studies with the CD40L-CD8 
fusion protein as the source of the CD40L stimulus. As 
depicted in Figure 1 B, OX4OL mRNA is almost undetect- 
able in unstimulated B cells, whereas it is significantly 
up-regulated after 24 and 38 hr of stimulation with the 
CD40L-CD8 fusion protein plus anti-IgD dextran. In addi- 
tion, we detected OX4OL mRNA in unstimulated and in- 
creased levels in anti-CD3-stimulated T cells (data not 
shown). Finally, we immunoprecipitated OX4OL using the 
0X40-immunoglobuiin fusion protein toverify the specific- 
ity of the 0X40-immunoglobulin/OX40L interaction. As 
shown in Figure 1 C, 0X40-immunoglobulincoated beads 
precipitated a 28-30 kDa protein, which could be com- 
peted with an excess of unbound 0X40-immunoglobulin 
and which was not found, when CD40-immunoglobulin- 
coated immunobeads were used in the assay. These data 
suggest that 0X40-immunoglobuiin interacts with the pre- 
viously described OX4OL molecule (Baum et al., 1994). 
On the basis of these findings, we used CD4OL L cells 
with or without anti-IgD dextran as primary B cell stimulus. 
When B cells were stimulated by anti-IgD dextran alone, 
we also included L cells (CD40L negative) in the assay. 
Both L cell lines express the human FcyllR (CD32). To 
investigate the effect of the 0X40-OX4OL interaction on B 
cell functions we added the 0X40-immunoglobulin fusion 
protein to the cell cultures, which bound to both L cell lines 
(via CD32), and thus was presented to the stimulated B 
cells. 
0X40-lmmuncglobulln Induces Enhanced 
B Cell Prcllferatlon 
Next, we determined the effect of OX4OL cross-linking 
proliferation of high density (resting) B cells. As sho 
in Figure 2, we found that while 0X40-immunoglobr 
induced no proliferation by itself, it greatly enhanced prc 
eration induced by CD40L or anti-IgD dextran. The m 
profound enhancement was observed with a combinat 
of both stimuli, correlating with the expression patterr 
OX4OL (see Figure 1A). Under these conditions, the efl 
of 0X40-immunoglobulin was dose dependent and, at 
highest investigated concentration (3 @ml), it resultec 
a [SH]TdR incorporation rate of more than 170,000 c( 
105 ceils @-fold above baseline stimulation), which Y 
accompanied by a parallel increase in the number c 
cells (data not shown). In contrast, control fusion prote 
(CD40-immunoglobulin, CTLA4-lg) or human IgG did 
induce B ceil proliferation (Table 1). Since it is known 1 
members of the NGFR superfamily (e.g., CD4OL) are 
voived in cell survival or cell death by apoptosis (F 
Apol), we determined the percentage of live cells (by 
pan blue exclusion) after culture with and without OX’ 
immunoglobulin. Under all incubation conditions no dl 
ences in cell survival were found between cultures \ 
and without 0X40-immunoglobulin (data not shown) 
Effects of OX40L Cress-Llnklng 
on B Cell Dlfferentlatlon 
in subsequent studies, we determined the effect of OX 
immunoglobulin (bound to L cells) on various events 
cell differentiation. These studies were conducted UI 
the same B cell stimuli as described above for the prolif 
tion experiments. 
Secretion 
As shown in Figure 3A, OX40 stimulation caused a si( 
cant increase in cumulative IgM secretin after 7 day 
addition, the dose-response curve for the IgM secretion 
dearly dependent upon the expression level of OX4OL 
der conditions that induce high OX4OL expression (CC 
plus anti-IgD dextran) maximal IgM response is reac 
at lower 0X40-immunoglobulin concentrations camp, 
with incubation conditions that induce lower OX401 
pression (CD4OL). Similar data were obtained for Igc 
cretion from splenic B cells and for IgA secretion of 
cells from the Peyer’s patch (Figure 3B). (The IgA seen 
of splenic B cells was very low and therefore not she 
Interestingly, thisstimulatoryeffectofOX4&immuno! 
ulin on B cell secretion isdecreased at high concentral 
of this fusion protein (Figures 3A and 38). This may k 
to a predominance of unbound 0X40-immunoglot 
which in turn leads to an inhibition of the cross-lir 
effect of membrane bound OX4Mmmunoglobulin. 
The increase in the cumulative immunoglobuiin SC 
tion after stimulation of B cells with 0X40-immunogio 
could have been due to increased immunogiobulin si 
tion per cell or to secretion by a larger portion of t 
cells. To investigate this question, we performed El 
assays for IgM secretion on B cells stimulated with Cl 
Lcelis in the presence or absence of 0X40-immunog 
lin. As shown in Figure 4A, the presence of 0X40-k 
Table 1. Influence of Cytokines on 0X40-lmmunoglobulin-Enhanced Proliferation and IgM Secretion 
B Cell Stimulus Proliferation (cpm) IgM Secretion (@ml) 
+ Cytokines 
CD4OL L cells 5,669 (f 676) 896 (f 210) 
+ 0X40-lmmunoglobulin 20.096 ( f 1,534) 5,853 (i 560) 
CD4OL L cells + IL4 30,290 (f 3,908) 473 ( f 62) 
+ OX40lmmunoglobulin 42,983 (f 3,609) 4.420 (f 340) 
CD4OL L cells + IL-5 12,377 (2 1,965) 2,576 (f 400) 
+ 0X40-lmmunoglobulin 34,747 ( f 3,016) 5,010 (f 672) 
CD4OL L cells + lL4/lL-5 26,132 ( f 5,378) 1,010 ( f 230) 
+ 0X40-lmmunoglobulin 46,974 (f 6,869) 5,200 ( f 670) 
CD4OL L cells + IL-6 5,778 ( f 1 .Z’E) 746(* 80) 
+ 0X40-lmmunoglobulin 19,069 (f 2,831) 5,656 ( f 546) 
CWOL L cells + IL-8/lL-5 15,462 ( f 454) 2,116(* 610) 
+ 0X40-lmmunoglobulin 35,658 ( f 2,608) 3,959 ( f 720) 
CWOL L cells + IL-10 4,531 (* 855) 396(* 145) 
+ 0X40-lmmunoglobulin 9,551 (f 2,735) 2.560 (k 384) 
CD40L L cells + IL-lo/IL-5 6,192 (* 1,169) 2,200 (* 610) 
+ 0X40-lmmunoglobulin 14,825 (f 3.211) 4,840 ( f 169) 
+ Anti-cytokine AB 
CD4OL L cells + algD dextran 38,650 ( f 3,400) 657(* 121) 
+ 0X40-lmmunoglobulin 125,560 (f 12,343) 2.830 (f 340) 
CD4OL L cells + algD dextran + all-2 65,743 (f 5,661) 850(* 180) 
+ 0X40-lmmunoglobulin 147,480 ( f 3,650) 3,830 ( f 580) 
CD40L L cells + a IgD dextran + alL4 41,895 ( f 9,560) 1,350 ( f 226) 
+ 0X40-lmmunoglobulin 148,690 (f 10,580) 2,376 ( f 450) 
CD40L L cells + alL-5 7,044 ( f 1,962) 823 (zt 72) 
+ 0X40-lmmunoglobulin 21,151 (i 924) 5,250 ( f 480) 
CD40L L cells + alL-6 4,332 ( f 289) 490 ( f 98) 
+ 0X40-lmmunoglobulin 18,665 (2 2,147) 5,010 (f 437) 
Control 
CD40L L cells 4,563 (f 500) 150(* 20) 
+ hulgG 3,665 ( f 372) 125 (& 35) 
L cells + algD dextran 867 (f 98) 23O(i 56) 
+ 0X40-lmmunoglobulin 14,142 (* 1,976) 1.546 (* 254) 
+ CMO-immunoglobulin 1,043(* 185) 350(* 65) 
+ CTLA4-immunoglobulin 976(* 132) 296(+ 112) 
High density splenic B cells (lo5 cells) were incubated with L cells plus algD dextran, CWOL L cells (B cell/L cell ratio, 1011) or CD4OL L cells 
plus a IgD dextran with or without 0X40-immunoglobulin (3 &ml, CD4OL L cells; 1 u mg/ml, L cells plus algD dextran; or 0.15 &ml, CD4OL 
L cells plus algD dextran, respectively) in the absence or presence of the following cytokines or anti-cytokine antibodies: IL4 (300 U/ml), IL-5 (100 
U/ml), IL-6 (25 @ml), IL-10 (25 @ml), alL-2 (1 &ml), all-4 (5 &ml), alL-5 (5 ug/ml), and all-6 (10 @ml). Human IgG (3 ug/ml), CTLAIlg and 
CD40-immunoglobulin (1 &ml) was used as control. Proliferation assays using PH]TdR were performed on day 3; cumulative IgM secretion in 
culture supernatants at day 7 was assessed using ELISA. 
noglobulin in the cultures resulted in significantly larger 
Elispots, indicating that an increased immunoglobulin se- 
cretion rate per cell is responsible for the observed effect 
on cumulative immunoglobulin secretion. The number of 
secreting cells were similar in the 0X46-immunoglobulin- 
treated cultures compared with the controls (aata not 
shown). Finally, as shown in Figure 48,0X46-immunoglob 
ulin-stimulated cells contained considerably increased 
levels of Cu mRNA after 6 days &fold increase as mea- 
sured by densitometry); this indicates that the enhanced 
immunoglobulin secretion rate is probably due to increased 
immunoglobulin heavy chain gene transcription. 
Since the effect of 0X40-immunoglobulin on B cell pro- 
liferation and immunoglobulin secretion could be an indi- 
rect effect mediated by one or more cytokines, rather than 
a direct effect on the B cell, we performed studies in which 
CD40Lstimulated B cells were incubated with or without 
0X46-immunoglobulin in the presence of cytokines or 
anti-cytokine antibodies. As shown in Table 1, addition of 
IL-5 (100 U/ml) to CD40L-activated B cell cultures en- 
hanced both proliferation and IgM secretion; however, this 
enhancement could always be further increased byOX40- 
immunoglobulin. Furthermore, the addition of monoclonal 
anti-IL-5 antibody to B cells stimulated with CD40L and 
0X40-immunoglobulin did not abolish the enhancing ef- 
fectsof 0X40-immunoglobulin. This suggests that neither 
exogenous or endogenous IL-5 seems to be involved in the 
enhancement of B cell proliferation and IgM secretion in- 
duced by 0X40-immunoglobulin. As also shown in Table 
1, parallel studies with other cytokines (114, 11-6, IL-lo) 
or monoclonal anticytokine antibodies (anti-IL-2, anti-lL4, 
anti-IL-6) showed that these cytokines also did not influ- 
ence the observed effect of OX4CQmmunoglobulin on B 
cell proliferation and IgM secretion. (The anti-IL-2 and anti- 
IL-5 antibodies were proven to be effective inhibitory anti- 
bodies in aTcell-induced B cell proliferation and differen- 
tiation assay; data not shown.) Thus, it appears that 
OX4OL cross-linking may have a direct effect on B cell 
OX40 Induces B Cell Proliferation and Differentiation 
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Figure 3. Induction of lmmunoglobulin Secretion with 0X40-lmmuno- 
globulin 
(A) IgM concentration of supernatants from B cells (IO5 cells) coincu- 
bated with L cells (B cell/L cell ratio, 10~1) (top) or CD40L L cells 
proliferation and differentiation and does not act thrc 
the cytokines tested. However, we cannot rule out 
certain combinations of cytokines or unknown cytok 
may be involved in B cell activation induced by 0) 
cross-linking. 
lmmunoglobulin lsotype Switch 
To investigate the effect of OX4OL cross-linking on iso 
switching by CD40L-stimulated resting B cells, we 
formed flow cytometry analysis (FACS) of such activ 
B cells at day 5 and day 7, to detect IgG- or IgA-poa 
cells. No differences between cells of cultures contai 
or not containing 0X48-immunoglobulin were obse 
(data not shown). To examine possible early switch ev 
being induced by OX4&immunoglobulin, we investig 
the expression of germline transcripts of all isot) 
which are early molecular markers of the isotype s\ 
process(Stavnezer-Nordgren and Sirlin, 1988). Using 
PCR techniques, we were unable to find difference 
0X49-immunoglobulin-treated versus untreated B 
with regard to their expression of germline transc: 
(data not shown). Thus, it appears that the increase< 
secretion by splenic B cells is a result of the stimulati 
postswitch B cells rather than caused by immunoglo 
isotype switch processes. 
Cell Surface Phenotype and Blimp7 Expression 
As a further assessment of the influence of 0X49-ir 
noglobulin on B cell differentiation, we investigate1 
effect of such stimulation on changes in the expre: 
of surface antigens that are known to occur in the cr 
of B cell terminal differentiation into plasma cells (Ha{ 
and Grosschedl, 1994; Sanderson et al., 1989; Reb 
al.,1993). The expression of surface IgM after 7 da 
stimulation with CD40L L cells in the presence or aba 
of 0X49-immunoglobulin is not altered by 0X40-imn 
globulin (data not shown); in addition, whereas sect 
IgM is increased by 0X40-immunoglobulin as shor 
Western blot (Figure 5A), no difference in the expre 
of mb-1 (Iga), CD19, syndecan, or PC-l was not 
0X40-stimulated cells compared with cells not recc 
that stimulus as shown in Figures 5A-5C. Fur-then 
we investigated the expression of Blimp-l, a nove 
finger transcription factor, which has been shown 
involved in multiple steps of B cell differentiation le 
to plasma cell development (Turner et al., 1994). Ass 
in Figure 5D, Blimp-l expression is not upregulai 
0X40-immunoglobulin-treated Bcells. These studie 
cate that while OX49 induces B cells to differentiat 
(bottom)withorwithout algDdextran(1 ng/ml)for7daysin theal 
or presence of 0X40-immunoglobulin (0.03-3 &ml). Data ref 
one of three to four separate experiments. 
(B) IgG (top) or IgA (bottom) concentration of supernatants from 
(splenic B cells in the case of IgG secretion and IgA+ B cells h 
Peyer’s patch in the case of IgA secretion) coincubated with 
or CD4OL L cells (B cell/L cell ratio, 1O:l) for 7 days in the a 
or presence of 0X40-immunoglobulin (0.03-3 uglml). Humi 
CTLWlg or CMO-immunoglobulin (as controls) did not enh 
cell immunoglobulin secretion under all investigated conditior 
not shown) 
B cells + CIMOL-L cells 
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Figure 4. Elispot Assay for Single Cell IgM Secretion and Northern 
Analysis for Cp mRNA Expression 
(A)Scellswere incubatedfor Gdays togetherwith CD4OL Lcells(Bcell/ 
6 cells producing large amounts of immunoglobulin, it 
does not induce plasma cell formation under the in vitro 
conditions tested. 
Effect of 0X40-lmmunoglobulin on the Expression 
of the Transcription Factor BSAP 
In previous studies, we and others showed that the tran- 
scription factor B cell lineage-specific activator protein 
(BSAP) has two binding sites in the immunoglobulin heavy 
chain gene 3’ a enhancer, occupation of which represses 
this enhancer (Singh and Birshtein, 1993; Neurath et al., 
1994). However, in vivo footprinting studies revealed that 
only BSAP site 1 is constitutively occupied in vivo in vari- 
ous B cell lines (Neurath et al., 1995). Since BSAP is not 
expressed in plasma cells, the enhancer is active in these 
cells, which is believed to be important for the high level 
immunoglobulin secretion of plasma cells (Neurath et al., 
1994). In view of these findings, we investigated the possi- 
bility that 0X40-induced effects on B cells might be medi- 
ated by its effect on cellular BSAP levels. Accordingly, 
we stimulated B cells with CD40L L cells with or without 
anti-IgD dextran or with anti-IgD dextran alone in the pres- 
ence or absence of 0X40-immunoglobulin. (Both of these 
stimuli have been shown to up-regulate BSAP levels; Wa- 
katsuki et al., 1994; Figure 6A.) After 2-7 days of culture, 
B cell nuclear extracts were prepared and electrophoretic 
mobility shift assays (EMSA) were performed using the 
H2A-2.2 binding site to detect BSAP. After 4 days of cul- 
ture, BSAP levels were first observed to be down-regulated 
by 30%-40% (data not shown) and, as shown in Figure 
6B, the addition of 0X40-immunoglobulin to stimulated 
B cells led to a 60%-60% reduction in BSAP levels after 
7 days. In addition, as shown in Figure 6C, parallel results 
were obtained when BSAP was measured by Western blot- 
ting, using a specific anti-BSAP antibody, indicating that 
the diminished BSAP DNA binding capacity is most likely 
due to decreased BSAP protein levels rather than to alter- 
ations of the protein (e.g., phosphotylation). In addition, 
using RT-PCR we showed that BSAP mRNA is also signifi- 
cantlydown-regulated byOX40-immunoglobulin(datanot 
shown). 
Interestingly, this effect of 0X40-immunoglobulin dif- 
fers from that obtained with various cytokines, which also 
stimulate immunoglobulin secretion. As shown in Figure 
6B, the addition of IL-5 and IL-6 to the cultures resulted 
in a significant up-regulation of BSAP expression, as mea- 
sured by EMSA and Western blot. Similarly, IL-4 and IL-1 0 
had the same positive effect on BSAP levels (data not 
shown). Since the effect of OX4OL cross-linking on BSAP 
expression was observed relatively late (maximum effect 
CD4OL L cell ratio, 1O:l) without (top) or with 0X40-immunoglobulin 
(bottom) (1.5 &ml). Cells were washed three times and subjected to 
Elispot analysis as described in Experimental Procedures. Cell clump 
ing was similar under both incubation conditions as controlled by light 
microscopy. Photomicrographs represent one of two experiments. 
(8) Total cellular mRNA (10 ug) per lane from spleen B cells stimulated 
for 4 or 6 days with CMOL L cells in the absence or presence of 
0X40-immunoglobulin or CTLA4-lg (1.5 @ml) was hybridized with 
a PCR-amplified “P-labeled Cp probe. Northern blot was subsequently 
washed and rehybridized with a 6-actin probe. 
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Figure 5. Expression of Plasma Cell Markers after OX4OL Cross-Linking 
B cells were incubated with CD40L L cells in the absence or presence of OX4&immunoglobulin (1.5 &ml, or as indicated) for 7 days. 1 
were then subjected to various analysis as follows: (A) Western blots for IgM (top) and CD19 expression (bottom); (8) Northern blot 
expression; (C) flow cytometric analysis of syndecan (top) and PC-1 expression (bottom). Rat (syndecan) or rabbit (PC-l) serum were 
control for unspecific staining. S194 and MPC-11 are murine plasmacytoma cell lines as positive controls. (D) Northern blot for Blimp-l exf 
RNA from the plasmacytoma cell line S194 was added as positive control. 
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Figure 6. Effect of OX4OL Cross-Linking on BSAP Expression 
(A) Nuclear protein (5 pg) from unstimulated B cells or from B cells 
stimulated as indicated for 7 days was incubated with radiolabeled 
H2A-2.2 reference binding site as described in Experimental Proce 
dures. Density of bands can only be compared within the indicated 
frames due to different exposure times of these independent experi- 
ments. 
(B) Nuclear protein (5 pg) from B cells stimulated as indicated for 7 
days (concentration of 0X40-immunoglobulin and CTLA4-lg: 1.5 pa/ 
ml) was incubated with radiolabeled H2A-2.2 reference binding site 
as described in Experimental Procedures. Density of bands can only 
be compared within the indicated frames due to different exposure 
times of these six independent experiments. 
(C) Nuclear protein (15 pg) from B cells stimulated as indicated were 
used for SDS-PAGE and Western blotting was performed as de- 
scribed using anti-BSAP-paired domain-specific antiserum. 
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Figure 7. In Vivo Footprinting of the lmmunoglobulin Heavy Chain 
3’ a Enhancer after OX4OL Cross-Linking 
B cells were stimulated with CD4OL L cells with or without 0X40- 
immunoglobulin (1.5 &ml) for 7 days. After in vivo treatment with 
DMSO, DNA was extracted and subjected to LM-PC&aided in vivo 
footprinting as described in Experimental Procedures. Results shown 
represent BSAP and NF-aP binding sites in the immunoglobulin heavy 
chain 3’a enhancer noncoding strand. The addition of IL-5 or human 
IgG (as control) did not change the in vivo footprinting pattern of 
CD4OL-stimulated B cells (data not shown). 
after 6-7 days), we cannot rule out that it is indirect. It is 
nonetheless important to note that OX40 is the only 8 cell 
stimulus reported so far that leads to a down-regulation 
in BSAP levels. 
Effect of OX40lmmunog/obul/n on the Binding of 
Transcrlption Factors to the 3’ a Enhancer in Vivo 
In previous studies, we have found that BSAP represses 
the immunoglobulin heavy chain gene 3’ a enhancer by 
inhibiting the binding of a second factor (NF-aP) to an 
adjacent downstream binding site (aP) (Neurath et al., 
1994, 1995). Thus, in plasma cells, which do not express 
BSAP, NF-aP can bind to this site and thereby activate the 
enhancer. In view of these results, we determined whether 
the negative effect of 0X40-immunoglobulin on BSAP ex- 
pression in CD40L-stimulated B cells was sufficient to re- 
sult in decreased binding of BSAP to its binding site in 
the immunoglobulin heavy chain 3’ a enhancer, thereby 
allowing the occupation of the aP site by NF-aP. Accord- 
ingly, we performed in vivo footprinting studies using liga- 
tion-mediated (LM)-PCR techniques to determine binding 
of proteins to regions of interest within the immunoglobulin 
heavy chain gene 3’ a enhancer. Indeed, as depicted in 
Figure 7, cross-linking of OX4OL on CD40L-activated B 
cells resulted in a loss of the footprint at BSAP site 1 and 
- + rabbi1 IgG 
-  + anti-Gx40 (11 
-  + anti-ox40 (2 
- 
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Figure 8. Inhibition of In Vii B Cell Function by Anti-OX40 Antib 
BALB/c mim were immunized with TNP-KLH in complete Fre 
adjuvant (100 pg, intraperitoneally) and treated with polyclonal I 
anti-murine OX40 (100 or 200 rg each injectiin) or rabbit IgG 
ug) on days O-6. Berum was collected after the indicated into 
and TNPapecific IgGl antibodies were determined as describ 
Experimental Procedures. Data represent one of two experime 
the appearance of a footprint at the aP site. Thus, stin 
tion of activated B cells with 0X40-immunoglobulin II 
to an occupancy pattern within the 3’ a enhancer sil 
to that observed in plasma cells (Neurath et al., 19! 
Blocking of the 0X40-OX4OL lnteractlon In Vivo 
Results in a Decreased Antibody Production 
In further studies, we examined the significance a 
0X40-OX4OL interaction in the course of a T cell-de 
dent B cell response in vivo by treating mice with anti-t 
antibodies, which could block this interaction. We t 
fore immunized mice with trinitrophenol-keyhole Ii 
hemocyanin (TNP-KLH) and subsequently treated 
with purified polyclonal anti-OX40 antibodies (100 a 
kg per injection) or rabbit IgG as control on day 0 and 
thereafter for 6 days. Serum anti-TNP IgGl concentrr 
were determined on days 7, 12, 17, and 22. As sho 
Figure 8, the treatment with anti-OX40 antibodies I 
a significant, dose dependent decrease in the prodr 
of anti-TNP IgGl at days 12-22. In contrast, the B 
anti-TNP IgGl levels were grossly unchanged (or 
increased at 200 pg anti-OX40) at day7 postimmuniz 
The essential role of physical contact between T cell 
B cells in B cell differentiation is well documented b! 
from numerous studies (Noelle et al., 1991; Hodg 
al., 1991; for review see Parker, 1993). While many 
effects brought @out by such contact are account 
by the CD40-CD40L interaction (Noelle et al., 1992; 
tage et al., 1992), this interaction cannot explain 
them. This was shown by the studies of Coffman 
(1988), for example, in which it was demonstrate 
resting B cells differ from activated B cells in their st 
tion requirements: whereas resting B cells need@ 
vated ThP-type T cell clones and their cytokines to i 
immunoglobulin secretion, large (presumably in vie 
activated) B cells undergo differentiation in the prs 
of activated THl T cell clones without ThP-type cyta 
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CD40-CD4OL interactions cannot explain this finding, be- 
cause CD40 is expressed by resting and activated B cells. 
In the present study, we have addressed the possible 
role of an alternative cell surface receptor-ligand pair, the 
0X40-OX4OL pair, which could possibly better explain the 
data of Coffman et al. (1988) since, in this case, the B 
cell surface molecule OX4OL is expressed only upon acti- 
vation. 
In initial studies, we showed that activation of murine B 
cells via surface IgD or through CD40 induces the majority 
of B cells to express OX4OL. The murine OX4OL molecule 
had an apparent molecular mass of approximately 28-30 
kDa, which corresponds to the published size of the cloned 
murine (28-28 kDa; Baum et al., 1994) and human OX4OL 
(34 kDa; Godfrey et al., 1994). The authors of these studies 
found OX4OL on activated T cells but did not find OX4OL 
expression on LPS-activated B cells as determined by 
FACS analysis and therefore concluded that OX4OL ex- 
pression on activated B cells was negligible. However, 
while LPS was also a weak stimulator of OX4OL expression 
in our experiments, B cell stimulation with anti-IgD dextran, 
CD4QL, or both led to strong OX4OL expression as shown 
by RT-PCR, immunoprecipitation, and FACS. Thus, OX4OL 
expression on B cells seems to depend on the B cell stimu- 
lus. We did confirm (by RT-PCR) the finding that OX4OL 
mRNA is also expressed by T cells, but the function of 
OX4OL on these cells still remains to be elucidated. 
In subsequent studies, we showed that OX40 stimu- 
lation of CD49stimulated B cells, anti-IgD dextran- 
stimulated B cells, or both led to increased B cell prolifera- 
tion and to an enhanced immunoglobulin secretion as 
compared with stimulation in the absence of OX4OL cross- 
finking. In the case of IgM, we showed by Elispot tech- 
niques that this enhanced secretion was due to an in- 
creased per-cell-secretion-rate rather than to an increased 
number of secreting cells. Furthermore, we demonstrated 
that this increased immunoglobulin secretion is probably 
due to enhanced immunoglobulin gene transcription, since 
OX4OL cross-linking increased the level of steady-state 
Cu mRNA, as demonstrated by Northern blot. In addition, 
we suggest that the effects of OX4OL cross-linking on B 
cell proliferation and secretion are independent of known 
exogenous or endogenous cytokines, since the addition of 
cytokines(IL-4, IL-5 IL-8, IL-lO)oranti-cytokineantibodies 
(anti-IL-e, anti-lL4, anti-IL5 anti-118) did not affect the 
OX4OL cross-linking effect. However, we cannot rule out 
that, under as yet untested conditions or in vivo, certain 
combinations of cytokines or uncharacterized cytokines or 
cell surface molecules may be involved in 0X40-induced B 
cell activation and differentiation. 
Additional studies of the effect of OX4OL cross-linking 
focused on certain events in B cell differentiation. First, 
using FACS for the detection of surface IgGllgA expres- 
sion and RT-PCR for germline transcript expression we 
showed that OX4OL cross-linking does not induce immu- 
noglobulin classswitching. Thus, the enhanced IgG secre- 
tion caused by OX4OL cross-linking on activated B cells 
is most likely due to an increased IgG secretion by already 
isotype-switched cells. This assumption is further strength- 
ened by the fact, that 0X40-immunoglobulin also stimu- 
lates FACS-purified IgA+ from the Peyer’s patch to prolifer- 
ate (data not shown) and to secrete IgA. Second, we 
showed that, while increased immunoglobulin secretion 
was induced by OX40 costimulation, the stimulated B cells 
retained a B cell phenotype: surface immunoglobulin, 
CD19, and mb-1 (lga) expression were not down- 
regulated, as they are in plasma cells, and established 
plasma cell markers (syndecan and PC-l) did not appear. 
In addition, the expression of Blimp-l, a recently described 
zinc-finger transcription factor involved in various steps 
of B cell terminal differentiation (Turner et al., 1994), is 
not induced by 0X40. However, even though we con- 
firmed that our detection method was functionally valid by 
the addition of a positive plasma cell control, we could not 
induce the investigated plasma cell markers with other 
stimuli in our culture conditions, using small resting B cells, 
either. Thus, future studies using different in vitro condi- 
tions or in vivo systems are necessary to investigate further 
whether OX4OL cross-linking is involved in plasma cell 
differentiation. 
Our further studies focused on possible molecular 
mechanisms underlying the OX40 costimulatory effect on 
immunoglobulin secretion. In these studies, we chose to 
investigate the transcription factor BSAP (Barberis et al., 
1990) because it has previously been shown to be in- 
volved in the regulation of B cell proliferation (Wakatsuki 
et al., 1994) and immunoglobulin secretion. BSAP is ex- 
pressed in all B cell developmental stages except for the 
plasma cell stage. In addition, it has been shown to occupy 
regulatory binding sites in the CD19 promoter (Kozmik et 
al., 1992) and various binding sites in the immunoglobulin 
heavy chain gene, including two binding sites in the immu- 
noglobulin heavy chain 3’ a enhancer (Petterson et al., 
1990; Dariavach et al., 1991). Recent work hasestablished 
that BSAP represses the 3’ a enhancer in B cells, so that 
in plasma cells, which do not express BSAP, the enhancer 
is active (Singh and Birshtein, 1993; Neurath et al., 1994). 
The mechanism by which this transcription factor exerts 
its repressor function on the immunoglobulin heavy chain 
gene 3’ a enhancer has recently been explored in our 
laboratory; it was demonstrated by using in vivo foot- 
printing techniques that the occupation of BSAP site 
l(BSAP site 2 is not occupied in vivo) inhibits binding of 
a newly described Ets-like transcription factor (NF-aP) to 
an adjacent downstream binding site, aP; thus if BSAP is 
not expressed (as in plasma cells) NFaP can bind to the 
aP site. It was further demonstrated by mutagenesis stud- 
ies that binding of NF-aP to the aP site is a necessary and 
sufficient stimulus for the activation of the immunoglobulin 
heavy chain gene 3’ a enhancer (Neurath et al., 1995). 
The functional relevance of these structural data was un- 
derscored by studies with triple helix-forming oligos spe- 
cifically targeting BSAP site 1. This treatment blocked the 
binding of BSAP to the 3’ a enhancer and resulted in the 
appearance of an in vivo footprint at the aP site, along 
with enhanced immunoglobulin mRNAand immunoglobu- 
lin protein expression (Neurath et al., 1995). 
In the present study, we showed that BSAP levels are 
down-regulated by 80%-80% in response to OX4OL 
cross-linking. The negative effect on BSAP expression 
:,X,40 Induces B Cell Proliferation and Differentiation 
was unique among all investigated B cell stimuli, including 
stimulation with LPS, anti-IgD dextran, CD4OL, and vari- 
ous cytokines that are known to induce immunoglobulin 
secretion by B cells. The extent of the down-regulation of 
BSAP was sufficient to result in its release from itsgenomic 
binding site 1 in the immunoglobulin heavy chain gene 
3’ a enhancer in vivo. This, in turn, led to the occupation of 
the aP site, as shown by in vivo footprinting, thus leading 
to an activation pattern of this enhancer in 0X40-immuno- 
globulin-stimulated B cells, as noted above. Thus, the in- 
creased immunoglobulin secretion rate after OX4OLcross- 
linking may be due to this observed effect in the in vivo 
binding pattern of the immunoglobulin heavy chain gene 3’ 
a enhancer. However, the level of cellular BSAP remaining 
after OX4OL cross-linking was probably sufficient to oc- 
cupy high affinity binding sites in the CD19 promoter 
(CD1 9 expression was not altered as shown by Western 
blot) and possibly in other promoter regions that are in- 
volved in the regulation of proliferation. Furthermore, it is 
important to note that we cannot rule out the possibility 
that other mechanisms are also involved in the observed 
effect of OX4OL cross-linking on B cell immunoglobulin 
secretion. Studies with recently published gene targeted 
mice lacking the immunoglobulin heavy chain gene 3’ a 
enhancer, which so far have been shown to exert profound 
defects in immunoglobulin isotype switch (Cogne et al., 
1994), will be necessary to explore this question further. 
To relate the present findings on OX40 costimulation of 
B cells in vitro to B cell responses in vivo, it is important 
to consider the fact that in the murine system, OX4OL- 
positive antigen-binding B cells are found in the PALS of 
spleens at day 3 after immunization with TNP-KLH (Cal- 
derhead et al., 1993). Jacobs and coworkers (1991,1992) 
have shown that these cells later proliferate and condense 
at day 4-6 to form large oligoclonal foci of highly immuno- 
globulin-secreting B cells around the PALS. This develop- 
ment reaches its peak around day 10 and then rapidly 
declines. Although these PALSassociated B cells un- 
dergo extensive IgM to IgG isotype switch (Kelsoe and 
Zengh, 1993), they are not believed to enter the memory 
cell compartment (Coico et al., 1963). The data presented 
in our study suggest that the 0X40-OX4OL interaction 
might be of importance for the above-mentioned series of 
events: we could show that B cells subjected to OX4OL 
cross-linking manifest an increased proliferation rate and 
enhanced immunoglobulin secretion, independent of the 
effect of various cytokines. Thus, the 0X40-OX4OL inter- 
action might be a T cell-dependent mechanism stimulat- 
ing B cells to produce large amounts of antibodies in the 
early phase of the immune response. Our in vivo studies, 
in which the 0X40-OX4OL interaction is blocked by anti- 
OX40 antibodies, resulted in a marked decrease in T cell- 
dependent B cell function as measured by anti-TNP- 
specific IgGl . These results underline the significance of 
our in vitro data concerning the 0X40-OX4OL interaction 
for the physiological in vivo situation and suggest that this 
interaction is a key aspect in terminal B cell differentiation 
in the primary immune response. Studies to determine 
the exact step in the cascade of T cell-dependent B cell 
activation, in which OX40 plays its important role and what 
this means for the development of plasma cells, gem 
centers, and memory cells, are currently underway 
published data). 
Expertmental Procedums 
Cell Prepamtion and Culture Conditions 
Female BALB/c mice (S-9 weeks old, NCVDCT) were sacrii 
spleens were removed and digested by collagenase (400 U/ml, E 
ringer Mannheim. Federal Republic of Germany) plus DNase 
mglml; Soehringer Mannheim, Federal Republic of Germany) at: 
for 15 min. The resulting splenocyte suspension was depleted c 
blood cells by hypotonic lysis with ACK lysing buffer (B and 6 I 
West Warwick, Rhode Island). Cells collected from the S9%-90% 
of a Percoll gradient centrifugation (Pharmacia Fine Chemicals, F 
taway, New Jersey) underwent further positive selection by sta 
with anti-mouse 8220 microbeads (Miltenyi Biotec, Bergisch 
bath. Federal Republic of Germany) and separation on a MAC! 
umn (Miltenyi et al., 1990) according to the protocol of the n 
facturer. The B cell suspension obtained by this procedure t 
95%-970/b purity, measured by FACS. For experiments cones 
IgA secretion, lymphocytes from murine Peyer’s patches wert 
pared as previously described (Harriman et al., 1999). Cells 
stained with goat anti-mouse IgA (Southern Biotechnology Assoc 
Birmingham, Alabama) and lgA+ B cells were purified by flow cyt 
ric sorting using the FACStar (Becton Dickinson, San Jose, Califc 
The purity was >99%. 
The L cell line expressing human Fcyll receptor (CD32) wa 
vided by Dr. K. Moore (DNAX, Palo Alto, California; Peltz et al., . 
The transfected L cell line expressing murine CD40L (hereafl 
ferred to as CD4OL L cells) (Wakatsuki et al., 1994) was a gifl 
Dr. Y. Wakatsuki (Kyoto, Japan). The murine plasma cell lines MI 
and 5194 were purchased from American Type Culture Co111 
(Rockville, Maryland). 
B cells were maintained in RPM1 1940 supplemented with 
fetal calf serum, 5% NCTC 109 media (Whittaker M. A. Biopro 
Walkersville, Maryland), 20 mM HEPES (National Institutes of I 
media unit), 2 mM Lglutamine (National Institutes of Health 
unit), 50 HIM &mercaptoethanol (Sigma Chemical Company, St. 
Missouri) and 10 U/ml penicillin, 100 @ml streptomycin (GIBCC 
Gaithersburg, Maryland). Media for the L cell lines contained, /I 
tion, HAT media supplement (Sigma Chemical Company, St. 
Missouri). CD4OL L cells were grown in the same media supplen 
with 6418 (1 mglml) (GIBCO BRL, Gaithersburg, Maryland 
plasma cell lines were grown in DMEM media (GIBCO BRL, Ga 
burg, Maryland). 
The following reagents and cytokines were used: the fusion 1 
OX4&immunoglobulin (0.03-3 VgIml) was made as previour 
scribed (Calderhead et al., 1993). Dr. R. Peach and Dr. D. Hollen 
(Bristol Myers-Squibb Pharmaceutical Research Institute, S 
Washington) provided the CD40-immunoglobulin and CT 
(0.03-3 pg/ml) fusion proteins. The CD4OL-CD9 fusion proteir 
cell culture supernatant) was provided by Dr. P. Lane (Basel, S 
land; Lane et al., 1993). Human IgG (0.03-3 kg/ml) was obtaine 
Sandoz (Basel, Switzerland), recombinant murine IL-5 (100 U/r 
generated as described previously (Kunimoto et al., 1991), re 
nant murine IL-4 (300 U/ml), IL-6 (25 @ml), IL-10 (25 @ml) ar 
mouse IL-2 (clone S4B9) (1 rg/ml) were bought from Pharmingc 
Diego, California), anti-mouse IL-4 (clone 11811) (5 pg/ml) w, 
vided by Dr. W. Paul (Bethesda, Maryland), anti-mouse IL-5 (5 
and anti-mouse IL-9 (10 nglml) were bought from Genzyme 
bridge, Massachusetts). Anti-mouse IgD dextran (1 @ml) w 
vided by Dr. C. Snapper (Uniformed Services University of 
Sciences, Bethesda, Maryland). 
Prollferatlon and Vlablllty Assays 
B cells (103 were coincubated for 72 hr with 1 x 10’ irradia 
kR) L cells or CD40L L cells, respectively, and the indicated rf 
and cytokines in flat-bottomed 96well plate (Costar Corporation 
bridge, Massachusetts). rH]TdR (1 pCi; specific activity, 6.7 C 
New England Nuclear) was added to each well for the last 
incubation. Each condition was done in triplicates. The cell 
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at the end of indicated culture periods was assessed by trypan blue 
exclusion. 
ELISA for lmmunoglobulln SecretIon 
Culture conditions were performed as described for the proliferation 
assays, with the exception that the incubation was allowed to take 
place for 7 days. Measurement of secreted immunoglobulin was done 
as previously described (Harriman et al., 1999). Unlabeled as well as 
alkaline phosphatase-conjugated goat anti-mouse IgM or IgG were 
purchased from Southern Biotechnology Associates (Birmingham, Al- 
abama). 
Ellapot for IgM Sacration 
B cells (IO? together with 1 x 105 L cells or CD4OL Lcells, respectively, 
were incubated for 6 days. At the end of the incubation period, cells 
were washed three times and incubated for 5 hr in OBwell plates 
(Costar Corporation, Cambridge, Massachusetts), which had been 
coated with goat anti-mouse IgM (Southern Biotechnology Associates, 
Birmingham, Alabama), as previously described (Lycke, 1986). Plates 
were washed, incubated with alkaline phosphatase-conjugated goat 
anti-mouse IgM (1:5OO)for2 hr at37OC, wash&again, and the alkaline 
phosphatase substrate (Western blue stabilized substrate for alkaline 
phosphatase; Promega, Madison, Wisconsin) together with 1% aga- 
rose gel was added. Color reaction was allowed to proceed for 24 hr 
before spots were counted and photographed. 
FACS 
Expression of B cell surface molecules was investigated by FACS 
using the FACScan from Becton Dickinson (San Jose, California) and 
the following antibodies or fusion proteins, respectively: 0X40-immu- 
noglobulin (15 @ml); goat anti-human IgG phycoerythrin (PE) (South- 
em Biotechnology Associates, Birmingham. Alabama); rabbit anti- 
mouse PC-1 antiserum (provided by Dr. S. Hickman, St. Louis, 
Missouri; Rebbe et al., 1993); rat anti-mouse syndecan (clone 28.1, 
a gift from Dr. M. Bernfield, Boston, Massachusetts; Sanderson et al., 
1989) PE-labeled goat anti-rabbit IgG or anti-rat IgG (purchased from 
Jackson Laboratories, West Grove, Pennsylvania) and goat anti- 
mouse IgM PE, anti-mouse IgG fluorescein isothiocyanate and anti- 
mouse IgA fluorescein isothiocyanate (obtained from Southern Bio- 
technology Associates, Birmingham, Alabama). Propidium iodide(Sigma 
Chemical Company, St. Louis, Missouri) was used to detect dead cells 
and eliminate them from data analysis. 
Immunopraclpltatlon 
B cells (2 x IO’) were incubated for 36 hr with anti-IgD dextran (1.5 
ng/ml)and with theCD4OL-CDEfusion protein(lO% cellculturesuper- 
natant). Cell surface proteins were biotinylated at the end of the culture 
period using Dbiotinoyl-s-aminocaproic N-hydroxysuccinimide ester 
(biotin-X-NHS) (Boehringer Mannheim, Federal Republic of Germany) 
as previously described (Meier et al., 1992). lmmunoprecipitation was 
performed as follows: cells were lysed in borate buffer (10 mM (pH 
8.01) containing 0.5% Triton X-100 for 1 hr at 4“C. The supernatants 
were precleared with 50 nl of rabbit anti-human FIT immunobeads 
(Irvine Scientific, Santa Ana, California) for 1 hr at 4OC. Subsequently, 
samples were centrifuged, 50 pl of 0X40-immunoglobulin (or CD40- 
immunoglobulin)coated rabbit anti-human Fc, immunobeads (Irvine 
Scientific, Santa Ana, California) were added and samples were incu- 
bated for 1 hr at 4OC. For competition studies, 10 x excess of unbound 
0X40-immunoglobulin was added to this step. Samples were centri- 
fuged, the pellet resuspended in SDS gel-loading buffer (100 mM Tris, 
200 mM DlT, 4% SDS, 0.2% BPB, 20% glycerol), heated for 5 min 
at 95OC and applied to a 10% Tris-glycine-polyacrylamide gel. After 
gel electrophoresis for 1 hr with 100 V, proteins were transferred to 
nitrocellulose filters (0.2 Cm, Schleicher and Schuell, Keene, New 
Hampshire), incubated in phosphate-buffered saline (PBS) with 3% 
nonfat dairy milk for 2 hr, and subsequently streptavidin-conjugated 
alkaline phosphatase (1:lOOO) (Boehringer Mannheim, Federal Re- 
public of Germany) was added for 2 hr. Color reaction was induced 
by Western blue stabilized alkaline phosphatase substrate (Promega, 
Madison, Wisconsin). 
Northern Blot Analysis 
Splenic B cells (2 x IO’-5 x IO’) were coincubated with or without 
2 x lb L or CD40L L cells and the indicated reagents or cytokines 
in Swell plates (Costar Corporation, Cambridge, Massachusetts) for 
the indicated periods of time. Cells were washed in PBS and total 
cellular RNA was extracted by the guanidine isothllcyanate method 
(Chomzcynski and Sacchi, 1997). RNA (10 ug) was applied to a 1% 
denaturing agarose gel, electrophoresed, and transferred to nitrocellu- 
lose filters (0.2 nm, Schleicher and Schuell, Keene, New Hampshire). 
Subsequently, blots were hybridized at 45OC in Hybrisol solution 
(Oncor, Gaithersburg, Maryland) overnight and washed in 2 x SSC 
plus 0.1% SDS. All cDNA probes for targeted mRNA were amplified 
by PCR (for primer sequences see below), electroeluted from agarose 
gels, and random labeled with [a-S2P]dCTP (10 mCi/ml) (Amersham, 
Arlington Heights, Illinois) using the random primer labeling kit by 
Stratagene (La Jolla, California). 
Western Slot Anatysls 
B cells were incubated as described for Northern blot analysis. After 
indicated periods of time, cells were resuspended (1 M NaCI, 0.01 M 
Tris [pH 7.61, 0.001 M EDTA (pH 8.01, 1 pglml aprotinin, 100 ug/ml 
PMSF) and subsequently denatured in SDS gel-loading buffer (see 
Immunoprecipitation). Protein concentrations were assessed with the 
Bradford assay using bicinchoninic acid (BCA) as a reagent (Bradford, 
1976) and equal amounts (20 ug) of each sample were applied to a 
10% SDS polyacrylamide gel. After electrophoresis, proteins were 
transferred to nitrocellulose membranes and pretreated for several 
hours in PBS containing 3% nonfat dry milk. Blots were subsequently 
incubated with antibodies overnight (goat anti-mouse IgM AP (1:200), 
anti-mouse CD19 (gift from Dr. J. Cambier, Denver, Colorado) or anti- 
BSAP-paired domain-specific antiserum Al (1:200), provided by Dr. 
Meinrad Buss-linger, Vienna, Austria), followed by a second incubation 
with alkaline phosphatase-conjugated goat anti-rabbit immunoglobu- 
lin (Jackson Laboratories) (1:200) in the case of BSAP and CD1 9 West- 
ern blots. Color reactions were induced by Western blue stabilized 
alkaline phosphatase substrate (Promega, Madison, Wisconsin). 
RT-PCR 
Total cellular RNA was prepared as described above, 2 pg of which 
was reverse transcribed according to standard protocols using M-MLV 
reverse transcriptasefrom GIBCO BRL(Gaithersburg. Maryland). The 
resulting cDNA was subjected to PCR amplification of targeted se- 
quences (for primers, see below): 37 PCR cycles at 94OC for 1 min, 
at 57OC for 1 min, at 72OC for 1 min (for a-GLT); 35 cycles at 94OC 
for 1 min. at 55°C for 1 min. at 72OC for 1 min (for yl, 72a, y2b, 73, 
EGLT, mOX4OL); 32 cycles at 94OC for 1 min, at 59OC for 1 min, and 
at 72OC for 1 min (for p-actin). 
Prsparatlon of Antl-OX40 Antlbodles 
0X40-immunoglobulin fusion protein (109 pg) in complete Freund’s 
adjuvant were subcutaneously injected into & to IO-week-old New 
Zealand White rabbits. Serum was collected after 4 weeks and ana- 
lyzed for antibody titers by enzymelinked immunosorbent assay 
@LISA). Antisera were subsequently treated with 45% saturated am- 
monium sulfate (Sigma Chemical Company, St. Louis, Missouri), the 
precipitate was dissolved in PBS, and dialysed against PBS overnight 
at 4OC. The resulting immunoglobulin-enriched antisera fraction was 
subsequently affinity purified as follows: first, the antisera were de 
pleted of their anti-human FQI antibodies by applying them to a col- 
umn (C 10/10column, Pharmacia Biotech. Piscataway, NJ) containing 
human IgGl (Calbiochem, San Diego, CA)-coated CnBr-activated 
sepharose beads (Pharmacia Biotech). Second, the resulting antisera 
were run over another ClO/lO column, which contained 0X40-immu- 
noglobulincoated sepharose beads. Bound antibodies were eluted 
from the column with a 100 mM glycine (pH 2.5) wash, which was 
collected in 1 M Tris-HCI (pH 7.4). Third, after another precipitation 
step with 45% saturated ammonium sulfate, the precipitate was dis- 
solved and dialysed as mentioned above. The resulting polyclonal 
rabbit anti-murine OX40 antibody-containing solutions were checked 
for their ability to bind to OX40 by ELISA and Western blotting tech- 
niques and found only to contain minimal (<5%) anti-human IgGl 
activity. The purity was assess& by SDS-PAGE analysis and the protein 
concentration was determined using the Bradford assay (1976). 
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In Vlvo Protocol for T Cell-Depandent B Cell Function 
TNP-KLH (100 pg in complete Freund’s adjuvant) was injected intra- 
peritoneally into 6- to Eweekold SALB/c mice. The animals were sub- 
sequently administered rabbit anti-OX40 (100 or 200 pg) or rabbit IgG 
as control (200 vg; Calbiochem) on days 0, 1,2.3,4,5, and 6 following 
the immunization. Serum was collected on days 7, 12, 17. and 22. 
Serum concentrations of anti-TNP IgGl antibodies were determined 
as described below. 
Assay for Antl-TNP IgGl 
TNP-bovine serum albumin (0.3 mglml) was bound to a g&well ELISA 
plate, which was subsequently blocked with 1% bovine serum albumin 
containing PBS and murine sera, diluted from I:100 to >1:100,000, 
were incubated for 2 hr at 37OC. The plates were washed and goat 
anti-murine IgGl conjugated to alkaline phosphatase (1:500) (South- 
ern Biotechnology Associates, Birmingham, Alabama) was added. 
Color reactions were performed as described above. To compare dif- 
ferent specimens, the OD, reading from the I:400 dilution was evalu- 
ated. This fell well within the linear part of the titration curve. 
Preparation of Nuclear Extracts 
Extractions of nuclear proteins were performed by the method of 
Schreiber et al. (1969). Protein concentrations were measured with 
the Bradford (1976) assay using BCA as a reagent. 
EMSA 
The H2A-2.2 reference binding site (Barberis et al., 1990) was used 
to detect BSAP levels by EMSA. Oligonucleotides for EMSA were 
end-labeled with [y-=P]ATP (>5000 Cilmmol; Amersham Corporation, 
Arlington Heights, Illinois) using bacteriophage T4 polynucleotide ki- 
nase (New England Biolabs, Beverly, Massachusetts), gel purified, 
and used for EMSA. 
EMSA studies lo detect BSAP levels were performed as described 
(Neurath et al., 1994). In brief, binding reactions (15 ~1) contained 2 
pg synthetic DNA duplex of poly(dldC) (Pharmacia Fine Chemicals, 
Piscataway, New Jersey), 25.000 cpm of end-labeled DNA probe, and 
incubation buffer (IO mM HEPES [pH 7.91, 100 mM NaCI. 10% glyc- 
erol, 0.5 mM MgCI,, 1 mM DTT). After preincubation without protein 
for 15 min at room temperature, crude nuclear proteins were added 
to the reaction for an additional 15 min and complexes were separated 
from unboundspecificprobe byelectrophoresisin native4% polyacryl- 
amide gels. After electrophoresis, the gels were dried and exposed 
to Kodak films on intensifying screens overnight at -60°C. 
In Vlvo and In Vitro Dlmethyl Sulfate-Plperldine 
Treatment of DNA 
Cells grown in suspension were washed twice with PBS, then resus- 
pended in RPM1 1640 media at l@ cells/ml. Incubation with dimethyl 
sulfate was performed for 1 min aI room temperature, followed by 
incubation in cell lysis buffer (1 mM Tris [pH 7.51, 400 mM NaCI, 2 
mM EDTA, 0.2% SDS, 0.2 mg/ml proteinase K) at 37OC. After extrac- 
tion with phenolchloroform, the methylated DNA was precipitated with 
ethanol and the strand scission reaction was performed in 1 M piperi- 
dine at 90°C. The DNA was then reprecipitated twice and used for 
the LM-PCR procedure described below. 
LM-PCR 
LM-PCR-aided in vivo footprinting was carried out as previously de- 
scribed (Pfeifer et al., 1969). For primer and synthetic linker sequences 
for LM-PCR, see below. In brief, primer annealing was performed with 
0.5 pmol of primer 1 for 2 pg genomic DNA. For primer extension, 
Sequenase 1 .O (United States Biochemical, Cleveland, Ohio) or Vent 
polymerase (New England Biolabs, Beverly, Massachusetts) was 
used. Linker ligation was performed overnight and exponential PCR 
amplification was done with primer 2 and the linker primer for 16 cycles 
(94OC for 1 min. T, plus 1°C for 2 min, 76OC for 3 min). Finally, a 
“P end-labeled third primer was added and a final PCR cycle was 
performed (94OC for lmin, T, plus l°C for 2 min, 76OC for IO min), 
followed by phenolchloroform extraction, ethanol precipitation, and 
analysis by 6% denaturing urealpolyacrylamide gels. 
Ollgonuclectlde Primer Sequences 
The following oligonucleotide primers were used for RT-PCR: for 
p-actin, 5’-TCT AGG CAC CAA GOT GTG ATG-3’ and 5’-GCA , 
TAG CAC AGC TTC TC-3’; for a-GLT, C’-CCA CAG GCA ATC / 
CACAGAG3’and 5’-ACATGTGATGCTGGCATCTG-3’; for-+( 
5’-AGC ACG CAT CTG TGG CCC I-IC CAG ATC T-3’ and 5’4 
GTC ACT GTC ACT GGC GCA GGG AAA T-3’; for $?a-GLT, 5’: 
ATG GGA TGA CCT GGA GC-3’ and 5’-ACC AGC TGA TCT ( 
CAT CT-3’; for yPb-GLT, 5%AT GGA AGA TCA GAG GAT GG-3’ 
5’;TGG GAA GGT GTG CAC ACA CTG CT-3’; for v3-GLT, 5%AG 
CAG CCT CAA GGA GA-3’ and 5’-GGT CAT &T CGC TCA 
CC3’; for E-GLT, 5’-TAG CTG AGG GCA CTG AGG CA-3’ and 5’-1 
GAT GAA TGG AGT AGC TC-3’; for Cp probe, 5%AC CTG 
CTA CCA GAA CA-3’ and 5’-CTG TGA GTC ACA GTA CAC AC-3 
Blimp-l probe, 5’-GCA GAT CTG GAG TCA TOT AC-3’ and 5’~ 
GGA GCC ATG AAT CTC AT-3’; for mbl probe, 5’-TOG GAG 
AT0 CCA GG-3’ and 5’-ATG CTG GAG TCA GAC ATA TG-3’; an 
mOX4OL, B’-GTG AAG ATG GAA AGC GTC CA-3’ and 5’-TCA 
GAC ACA GAA TTC AC3’. 
The primer sequences for LM-PCR were as follows: primer I 
ber 1 , 5”TTC TGG GAT ACC CAG GAT lTG GAG C-3’; primer nul 
2,2.5’-ACC CAG GAT TTG GAG CAC ACC TAC A-3’; primer nul 
3, 5’-TGG AGC ACA CCT ACA GCC TTC CTG C-3’. Linker PI 
sequences were as follows: J’-GCG GTG ACC CGG GAG ATC 
ATT C-3’ and 3’-CTA GAC lTA AG-5’, respectively. 
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